Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications

References

• Druker BJ, Talpaz M, Resta DJ, . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Sawyers C. Chronic myeloid leukemia. N Engl J Med 1999;340: 1330–1340.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Melnick JS, Janes J, Kim S, . An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006;103:3153–3158.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, . Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, . Dasatinib inhibits the proliferation and function of CD4+ CD25+ regulatory T cells. Br J Haematol 2009;144:195–205.
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, . Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008;36:1297–1308.
   PubMed Web of Science ®Google Scholar
• Garcia-Munoz R, Galar A, Moreno C, . Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma 2007;48:2461–2464.
   PubMed Web of Science ®Google Scholar
• Torres HA, Chemaly RF. Viral infections or reactivation in patients during treatment with dasatinib. A call for screening. Leuk Lymphoma 2007;48:2308–2309.
   PubMed Web of Science ®Google Scholar
• Safdar A, Raad II. Management and treatment. In: O'Grady N, Pittet D, editors. Catheter-related infections in the critically ill. Boston: Kluwer Academic; 2004. pp 99–112.
   Google Scholar
• Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 2007;45:228–233.
   Google Scholar
• Ascioglu S, Rex JH, de Pauw B, . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7–14.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094–1097.
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Rolston KVI, . Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247–259.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, De Lima MJ, . Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine 2007;86:324–333.
   PubMed Web of Science ®Google Scholar
• Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000;254:1–13.
   PubMed Web of Science ®Google Scholar
• Harder KW, Quilici C, Naik E, . Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood 2004;104:3901–3910.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Deininger M, . Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200–1206.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Lévy V, . Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136–4147.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim DW, Raffoux E, . Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176–2183.
   PubMed Web of Science ®Google Scholar
• Kerkelä R, Grazette L, Yacobi R, . Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–916.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22: 409–429.
   PubMed Web of Science ®Google Scholar
• Grichnik JM, Burch JA, Burchette J, . The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233–238.
   PubMed Web of Science ®Google Scholar
• Huang X, Patel S, Ahmed N, . Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther 2009;2:215–219.
   PubMedGoogle Scholar
• Chaudhary LR, Hruska KA. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J Cell Biochem 2001;81:304–311.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen J, Jin D. Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor beta. Biochem Biophys Res Commun 1998;251:190–194.
   PubMed Web of Science ®Google Scholar
• Tasigna (nilotinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
   Google Scholar
• de Lavallade H, Punnialingam S, Milojkovic D, . Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008;141:745–747.
   PubMed Web of Science ®Google Scholar
• Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513–609.
   PubMed Web of Science ®Google Scholar
• Westhoff MA, Serrels B, Fincham VJ, . SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol 2004;24:8113–8133.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, O'Brien S, . Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
   PubMed Web of Science ®Google Scholar